NewsBenzinga報告:VirのElebsiranとTobevibart、ECLIPSE 1第3相B型肝炎デルタ試験で主要評価項目を達成、44%がウイルス検出不能とALT正常化を達成、遅延治療群は0% 報告:VirのElebsiranとTobevibart、ECLIPSE 1第3相B型肝炎デルタ試験で主要評価項目を達成、44%がウイルス検出不能とALT正常化を達成、遅延治療群は0% Benzinga 2026.11.09 07:49 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide